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We have previously reported that interleukin 10 (IL-10) signalling stimulated activation of a specific enhancer element, termed HTE-1,
to promote tissue inhibitor of matrix metalloproteinase1 (TIMP-1) expression in human bone metastatic PC-3 subclone (PC-3 ML)
cells. Recently, we have identified an IL-10 responsive signal molecule, termed IL-10E1, which binds the HTE-1 element and cloned
the gene encoding for the 22kDa protein. In this paper, we have examined the mechanism of IL-10/IL-10 receptor signalling in two
distinct human prostate cell lines, a ‘normal’ prostate epithelial cell line, termed NPTX-1532 and highly metastatic PC-3 ML tumour
cells. Signalling cascade studies revealed that IL-10 stimulated tyrosine phosphorylation of JAK1 and TYK2 receptor kinases and
tyrosine phosphorylation of IL-10E1. Phosphorylation, triggered IL-10E1’s rapid translocation to the nucleus by 10–30min. Deletion
analysis combined with transient transfection experiments revealed that the n-terminal domain (B74a.a.) of the IL-10E1 protein, the
nt-nls peptide, was stimulated by IL-10 to translocate to the nucleus and induce TIMP-1 expression. Site-directed mutagenesis further
showed that phosphorylation of two tyrosine moieties (Y57 and Y62) of the nt-nls peptide was required for IL-10 activation of
signalling and TIMP-1 expression. The data demonstrate, for the first time, that IL-10 receptor signalling of TIMP-1 expression is
regulated by tyrosine phosphorylation of a novel gene, IL-10E1, in human prostate cells.
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Changes in the relative levels and molar ratios of TIMPs and the
MMPs are implicated in normal and pathological processes such as
cancer, which involve connective tissue remodelling or degrada-
tion (Leco et al, 1992). Currently, it is thought that differential
regulation of these genes might be achieved, in part, by various
cytokines and growth factors, which allow responsive elements to
either cooperate with or antagonise each other to modulate the
expression of these genes (Leco et al, 1992). For example, there is a
multiplicity of agents found to stimulate tissue inhibitor of matrix
metalloproteinase1 (TIMP-1) expression in a variety of normal and
malignant cell cultures. These range from serum, TNF a, bFGF,
PDGF, EGF, phorbol esters, interleukin (IL)-1, IL-1 b, Il-6, and IL-
11 (MacNaul et al, 1990; Campbell et al, 1991; Carcolo et al, 1991;
Wright et al, 1991; Edwards et al, 1992; Roeb et al, 1993). In
addition, inhibition of TIMP-1 expression occurs in several
malignant cell lines in response to TGF b, all-trans-retinoic acid,
female sex hormones, and dexamethasone (Campbell et al, 1991;
Wright et al, 1991).
The regulation of TIMP-1 vs MMP expression may depend on
specific receptor-mediated transactivating signals and/or promoter
elements. For example, IL-6 stimulated TIMP-1 synthesis, but had
no effect on MMP synthesis (Lacraz et al, 1993, 1995); TGF b
simultaneously increased TIMP-1 mRNA levels while decreasing
MMP-2 mRNA content in fibroblasts (Overall et al, 1989); and
steroids suppressed the expression of MMPs while simultaneously
stimulating TIMP-1 production in uterine cervical fibroblasts (Sato
et al, 1991). Similarly, interleukin-1 and TNF a were found to
stimulate TIMP-1 production while up regulating MMP synthesis
in cultured chondrocytes (Chua and Chua, 1990; Lotz and Guerne,
1991; Martel-Pelletier et al, 1991). However, in fibroblasts
interleukin-1 and TNF a had little effect on TIMP-1 expression
(MacNaul et al, 1990). The implication is that cell-type-specific
signal cascades regulate gene expression.
Studies designed to identify determinant promoter regions and
related transacting factors, which control TIMP-1 and MMP
expression, would greatly aid in understanding the basis for
differential regulation of these proteins in specific cell types. In this
regard, we have examined the mechanisms regulating TIMP-1
expression in human prostate lines derived from nonmalignant
and malignant tumours. Preliminary studies of the TIMP-1
promoter revealed that TIMP-1 expression was controlled, in part,
by an 18bp enhancer element (CACGATGACTCATCACTG),
termed HTE-1, located in intron 1 upstream ( 847 to  865bp)
of the 50 ATG translational start site. Gel shift and chloramphenicol
acetyl transferase (CAT) assays with promoter constructs demon-
strated that the enhancer element binds a tentative regulatory
protein(s), which was selectively expressed by nonmetastatic PC-3
subclones (i.e. 2 X N.I. PC-3 subclones which fail to metastasise
when implanted in SCID mice) and not by the bone metastatic PC-
3 subclone PC-3 ML human tumours (Wang et al, 1998).
Moreover, and IL-10 independently stimulated a 7–9-fold increase
in pCAT-HTE-1-driven CAT activity and TIMP-1 expression in
transfected PC-3 ML cells. In addition, we found that IL-10, IL-4,
and IL-6 differentially regulate TIMP-1, MMP-2, and MMP-9
mRNA and protein expression in HPV-18 immortalised human
prostate cell lines derived from low and high Gleason score cancer
tissue (Stearns et al, 1995). Western blot and Northern blot
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sanalysis clearly demonstrated that IL-10, IL-6, and IL-4 all
upregulated TIMP-1 expression. In contrast, IL-10 and IL-4 (but
not IL-6) downregulated MMP-2 mRNA and protein levels (Stearns
et al, 1995). The data suggest that cytokine upregulation of TIMP-1
and coordinate downregulation of MMP-2 expression might
control the molar ratio of TIMP-1 and MMP-2 to influence the
level of protease activity and invasive behaviour of malignant
prostate cancer cells.
In this paper, we have extended the initial studies to investigate
the role of IL-10 receptor (IL-10R) signalling in the regulation of
TIMP-1 expression in nonmalignant primary human prostate
NPTX-1532 cell lines and malignant human prostate PC-3 ML cell
lines. A novel IL-10 responsive signal molecule, termed IL-10E1,
was identified which binds the HTE-1 element of the TIMP-1
promoter. We found that IL-10 triggered tyrosine phosphorylation
of the IL-10R and the IL-10E1 protein to activate translocation of
the IL-10E1 to the nucleus. Deletion analysis and site-directed
mutagenesis showed that IL-10 specifically triggered tyrosine
phosphorylation of tyrosines Y57 and Y62 to activate IL-10E1
signalling events and stimulate TIMP-1 expression. These data
demonstrate for the first time that a novel IL-10 signal cascade
regulates TIMP-1 expression in human prostate lines.
Note that the PC-3 ML and NPTX-1532 cells were selected for
the signalling studies as both cell lines expressed the IL-10R, but
only the PC-3 ML cells expressed detectable levels (i.e. in the 10–
30pg range) of the IL-10E1 protein. Thus, in the IL-10E1
transfection experiments, the translocation of the IL-10E1 protein
(or truncated IL-10E1 fragments) to the nucleus could be
examined in the presence or absence of endogenous IL-10E1.
MATERIALS AND METHODS
Cell cultures
We examined IL-10E1 expression in a variety of primary prostate
cell lines. The NPTX-1532 and CPTX-1532 cells (generously
provided by Drs Robert Bright and Susan Topalian, NIH-NCI,
Bethesda, MD, USA) are normal prostate culture developed from
normal prostate tissue extracted from human patients (Bright et al,
1997). These cells were immortalised with E6 and E7 transforming
proteins of human papilloma virus serotype 16 and were
maintained in Keratinocyte SFM (GIBCO BRL, Grand Island, NY,
USA) containing 50mgml
 1 bovine pituitary extract, 5ngml
 1
epidermal growth factor (EGF), and 5% foetal bovine serum
(Biofluids, Rockville, MD, USA). Both MGEM and Keratinocyte
SFM media contained 100Uml
 1 of penicillin G sodium and
100mgml
 1 streptomycin sulphate. Cells were routinely passaged
by mild Trypsin–EDTA (GIBCO BRL, Grand Island, NY, USA)
detachment and cultured in a humidified atmosphere of 95% air
and 5% CO2 at 371C. HPV-MLC7 cells (kindly provided by Dr
Donna Peehl, Stanford University, CA, USA) are benign prostatic
hyperplasia culture immortalised by human papilloma virus
serotype 18 (Cohen et al, 1991). The HGPIN cell line was
established in our laboratory from human prostate tissue showing
high-grade prostatic intraepithelial neoplasia (HGPIN) histology.
The HGPIN cultures were immortalised by HPV-18 transfection
according to published methods (Wang et al, 1996). The BPH and
HGPIN cell lines were maintained in Keratinocyte SFM (Gibco
BRL, Grand Island, NY, USA) containing 5ngml
 1 EGF,
50mgml
 1 bovine pituitary extract, and 5% foetal bovine serum
(Biofluids, Rockville, MD, USA). All the different cell lines were
transferred to their respective medium containing 10nM DHT and
10mM HEPES buffer, but without supplements (i.e. pituitary
extracts and ITS) for 1h prior to carrying out the IL-10 studies.
The 2 X N.I. PC-3 subclones and the bone metastasising PC-3
ML subclones derived from the parent human prostate PC-3 line
were grown as previously described by our laboratory (Wang et al,
1998). In transfection experiments, the cell cultures were
transiently transfected overnight and the cells exposed to IL-10
prior to harvesting and protein extraction from the cytoplasmic
and nuclear compartments (Stearns et al, 1995). Unless stated
otherwise, the cells were treated with IL-10 at 15ngml
 1 for 1h in
all the experiments.
Cloning the IL-10E1 gene
mRNA was isolated from PC-3 ML cells using a mRNA purification
kit (PolyATtract system 10000, Promega, Madison, WI). A phage
vector ZAP-express vector (Stratagene, La Jolla, CA) was used to
construct a cDNA library. Clones were screened three times
according to Singh et al (1998) with a
32P-labeled oligonucleotide
containing three repeats of the HTE-1 sequence. Positive phages
were treated by in vivo excision to form a phagemid containing the
cloned insert using a protocol described by the instruction manual
of ZAP-cDNA Gigapack II Gold Cloning kit (Stratagene, La Jolla
CA). The IL-10E1 cDNA was cloned in a GST-vector pGEX4T2
vector. The GST–IL-10E1 fusion protein was isolated using a
glutathione Sepharose 4B beads, and IL-10E1 was purified utilising
thrombin protease (27-0843-01) cleavage to separate IL-10E1 and
GST proteins according to the methods of the manufacturer
(Pharmacia Biotech, Piscataway, NJ, USA).
Sequencing
DNA sequencing was done using ABI 377 and 373 A Stretch
sequencers with Taq FS Dye Terminator or Dye Primer chemistry
(DNA Sequencing Facility, University of Pennsylvania, USA). The
protein sequence was deduced from the cDNA sequence using a
GCG program. Peptide fragments generated from purified IL-10E1
protein were sequenced by the protein sequencing facility
(University of Pennsylvania). Protein purity was verified by
SDS–PAGE analysis.
Electrophoretic mobility shift assays (EMSAs)
Cytoplasmic and nuclear proteins were prepared using published
protocols (Wang et al, 1998). Crude extracts from recombinant
phage lysogens were prepared as described by Singh et al (1998).
The DNA–protein binding reaction and EMSA were carried out as
described by Singh et al (1998). The DNA binding reaction mixture
contained B100000c.p.m. of the
32P-end-labelled double-stranded
oligonucleotide (B1ng), plus B5mg of crude protein extract, 1mg
of poly (dI-dC)-poly (dI-dC) (Sigma) and buffer composed of
10mM HEPES (pH 7.9), 50mM NaCl, 1mM DTT, 1mM EDTA, and
5% glycerol. Samples were eluted on 8% SDS–PAGE gels and
developed by autoradiography overnight.
ELISAs
ELISAs (A 490nm) were performed according to methods
previously described (Stearns et al, 1995) using well-characterised
polyclonal antibodies specific for TIMP-1 (Stearns et al, 1995). We
used the TIMP-1 antibody at a dilution of 1:2000 (500ngml
 1)
and recorded the absorbance (A 490) for three different dilutions
(B5, 7.5, and 10mgml
 1 protein) of conditioned medium from
NPTX-1532 cells. Cells were plated on human collagen IV
(100mgwell
 1 in 12 well dishes) at 1 10
6 cellsml
 1 for 24h and
exposed to IL-10 for 24h prior to collecting the conditioned
medium. The measurements were normalised to 10mgml
 1
protein and the total amounts of antigenml
 1 determined from
an ELISA standard curve (Stearns et al, 1995). Protein levels were
measured according to the methods of Bradford (1976).
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sSite-directed mutagenesis
Site-directed mutagenesis and deletion analysis were carried out
according to the methods described by Sambrook et al (1989). The
deleted or mutated fragments were generated from the IL-10E1
cDNA using specific primers and PCR (B35 cycles amplification).
The fragments were then subcloned and sequenced (DNA
Sequencing Facility, University of Pennsylvania) to confirm the
specific deletions and mutations.
Subcloning the IL-10E1 fragments
To generate the different IL-10E1 subclones, ZAP-cDNA synthesis,
ligation of the ZAP-cDNA into the Uni-ZAP XR vector arms, and
packaging of recombinant phage DNA were performed using a
lambda phage vector-ZAP Express cDNA vector and protocol of
the ZAP-cDNA Gigapack
R II Gold Cloning Kit (Stratagene Inc., San
Diego, CA, USA). The cDNA fragments cloned encoded for the
following peptide fragments of the IL-10E1 gene, including:
Amino acids bolded and underlined were mutated. The nuclear
localisation signal (nls) was bolded.
Mc 61¼mutant tyrosine 61.
Transient transfection experiments
NPTX-1532 or PC-3 ML cells were transfected overnight with 4mg
of recombinant phagemid using 8mg of Lipofectin reagent
according to protocol described by the manufacturer (Gibco Life
Technologies Inc., Boston, MA, USA). Western blots were
according to the methods of Towbin et al (1979).
Source of reagents
The following indicate the reagents (source): IL-10 (Schering
Corp., Kenilworth, NJ, USA); IL-10 and IL-10 receptor antibodies
(Schering Plough; Kevin Moore, DNAX Inc., San Diego, CA, USA);
(Liu et al, 1994); rabbit antibodies against human JAK1, JAK2,
TYK2 (UBI, Inc. Saranac Lake, NY, USA); Protein A–Sepharose
and Protein-G Sepharose beads (Pharmacia, Piscataway, NJ, USA);
PVDF membranes (Immobilon-P, Millipore, Bedford, MA, USA).
Antiphosphotyrosine antibody PY20 (Sigma Sci., St Louis, MO,
USA).
RESULTS
Cloning of IL-10E1 gene
An IL-10 responsive signal protein, termed IL-10E1, was cloned
from a phage expression cDNA library utilising a triplicate repeat
of the HTE-1 sequence, an enhancer element of the TIMP-1
promoter (Wang et al, 1998). In preliminary studies, EMSAs
showed that a protein present in lysogen extracts from rIL-10E1
recombinant phagemid clones binds the HTE-1 oligonucleotide
(Figure 1, lanes 1–2). The band shift mobility was identical to that
observed with the native protein isolated from human prostate PC-
3 ML cells (Figure 1, lane 3) and rIL-10E1 protein extracted from
rIL-10E1 transfected NPTX-1532 cells (Figure 1, lane 4). In
comparison, protein from a randomly selected phagemid clones
(Figure 1, lane 5) and the bacteria extract alone (Figure 1, lane 6)
failed to bind the HTE-1 probe. In control experiments, the nuclear
protein extracts were obtained from PC-3 ML cells exposed to IL-
10 in the presence of IL-10R antibodies (1:100 dilution) (Figure 1,
lane 7), or the protein extracts were preincubated with excess ‘cold
HTE-1 oligonucleotide’ at concentrations ranging from 10ngml
 1
for 30min (Figure 1, lane 8). Note that a total of five separate rIL-
10E1 phagemid clones derived from three different cDNA libraries
yielded a recombinant protein that bound the HTE-1 probe.
Sequencing
Sequencing of three independently derived IL-10E1 clones revealed
that the IL-10E1 gene was B95% homologous with CSRP-2 and
hsmLIM domain genes (Weiskirchen et al, 1997).
IL-10E1’s homology with CSRP-2 and hsmLIM was reduced to
B90% in a region spanning exons 2 and 3 (i.e. B+451 to +490bp)
IL-10E1: 
nt: MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSKAVA 
IHDEEI
nt-mC61:
MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSKAVA 
IHDEEIYCKSGYGKKYGPKGYGYG
nt-nls: MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSKAVA 
IHDEEIYCKSCYGKKYGPKGYGYG
nt-nls mY57/mY62:
MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSKAVA 
IHDEEILCKSCLGKKYGPKGYGYG
ct:    
GKKYGPKGYGYGQGAGTLNMDRGERLGIKPESVQPHRPTTNPNTSKFAQKYGG
AEKCSRCGDSVICCRKDNWSWKALAQKLFPMCKFW
mY57/mY62 = mutant tyrosine 57 / mutant tyrosine 62. ct = c-terminal
domain of IL-10E1.
Diagram 1: IL-10E1 constructs 
IL-10E1:                        5’        
nt:
nt-nls mC61:                  YCKSGYGKKYGPKGYGYG
nt-nls:     CYGKKYGPKGYGYG
nt-nls mY57/MY62: LCKSCLGKKYGPKGYGYG
ct: GKKYGPKGYGYG
1 2 3 45 6 7 8
Lanes
Figure 1 Electrophoretic mobility shift assays (EMSAs) showing that the
32P-end-labelled double-stranded HTE-1 oligonucleotide (B1ng,
B100000c.p.m.) binds rIL-10E1 protein and native nIL-10E1 protein
(5mg/lane
 1) from PC-3 ML cells. The probe was incubated with protein
(5mg) from (lanes 1–2) two rIL-10E1 phagemid clones; (lane 3) PC-3 ML
cells (nIL-10E1); (lane 4) rIL-10E1-transfected NPTX-1532 cells; (lane 5) a
phagemid clone and (lane 6) a bacteria culture. In control experiments
(lane 7), the nuclear protein extracts were obtained from PC-3 ML cells
exposed to IL-10 in the presence of IL-10R antibodies (1:100 dilution); or
(lane 8) from IL-10-treated cells where the nuclear protein extracts were
preincubated (for 30min) with excess ‘cold-HTE-1 oligonucleotide’ at
concentrations of 10ngml
 1, which competitively blocked labelled
oligonucleotide binding to rIL-10E1 protein.
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s(Weiskirchen et al, 1997). The deduced amino-acid sequences
revealed that the IL-10E1 protein had an open reading frame
of 192 amino acids (a.a.) (B22kDa) (Figure 2). A classical
LIM-domain sequence (CX2C17HX2CX2C17CX2C) was detected in
the n-terminal region with a GY-rich box tail (bolded) and a
nuclear localisation signal-(underlined) (YCKSCYGKKYGPK-
GYGY).
Western blot studies
Rabbit polyclonal antibodies were generated against a 22a.a.
peptide (YCKSCYGKKYGPKGYGYGQGAG) located near the n-
terminal domain of the IL-10E1 protein (see diagram 1 in Materials
and Methods and Figure 2). Western blot analyses on whole-cell
extracts demonstrated that IL-10E1 was expressed at roughly
equivalent levels in PC-3 ML and CPTX-1532 cells (Figure 3, lanes
1–2), but was not expressed in the four different BPH, two HGPIN
and the four different NPTX-1532 cell lines (Figure 3, lanes 3–12,
respectively). Note that CPTX-1532 cells are a malignant primary
prostate line derived from the same prostate as the normal NPTX-
1532 cells. Western blots further showed that the IL-10E1
antibodies specifically recognised the rIL-10E1 protein (22kDa,
Figure 4A, lane 5).
Truncated peptide fragments of the IL-10E1 protein were
produced for studies of the role IL-10E1 in IL-10R signalling (see
Diagram 1). Western blots also showed that the IL-10E1 antibodies
recognised peptide fragments of the IL-10E1 protein, which, were
isolated from recombinant phagemid clones expressing truncated
rnt-nls; rnt-nls mC61, and rnt-nls mY57/mY62 peptides (Figure 4A,
lanes 1–4, respectively). Note that the samples were eluted on a 8–
15% gradient gel and the peptide fragments appear to vary in size
slightly as a result of one or two amino-acid differences in the
amino-acid sequence (Figure 4A). Interestingly, the IL-10E1
antibodies recognised the rnt-nls-peptides (Figure 4B, lane 1)
and binding was specifically competed by preabsorbing the
antibody with rIL-10E1 protein (Figure 4B, lane 2). However, the
antibodies failed to bind rct and rnt peptides, respectively
(Figure 4B, lanes 3–4), which were generated from the c-terminal
domain of the IL-10E1 protein and missing the ‘YCKSCYGK-
KYGPKGYGY’ region of the rnt-nls peptide.
Western blotting studies further showed that following transfec-
tion of NPTX-1532 cells with either rnt-nls, rnt-nls mC61, or rnt-
nls mY57/mY62 constructs (Figure 4C, lanes 1–3), respectively,
the truncated peptides and the intact protein were expressed in
crude cytoplasmic extracts of the cells.
IL-10 signalling studies
These studies were initially carried out in a normal NPTX-1532
prostate cell line, which expressed barely detectable levels of
TIMP-1 and which failed to express endogenous IL-10 E1.
Following transient transfection of the NPTX-1532 cells with the
rIL-10E1 construct, cells were treated with IL-10 (15ngml
 1 for 0–
120min). Western blots of nuclear and cytoplasmic protein
extracts revealed that rIL-10E1 was present in cytoplasmic extracts
at time zero and after 10min stimulation with IL-10 (Figure 5,
lanes 2, 4, respectively). rIL-10E1 was not detected in the nuclear
           1                                                          50
IL-10E1   MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSKAVA 
rsmLIM MPVWGGGNKCGACGRTVYHAEEVQCDGRTFHRCCFLCMVCRKNLDS  TTVA
hsmLIM   MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDSHAVA 
hCRP2 MPVWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDS  TTVA
cCRP2 MPNWGGGNKCGACGRTVYHAEEVQCDGRSFHRCCFLCMVCRKNLDS TTVA
NC                         /                                 /// 
                                  100
IL-10E1: IHDEEI  YCKSCYGKKYGPKGYGYGQGAGTLNMDRGERLGIKPESVQPHRP 
rsmLIM  IHDEEI  YCKSCYGKKYGPKGYGYGQGAGTLNMDRGERLGIKPESAQPHRP
hsmLIM    IHDEE-  YCKSCYGKKYGPKGYGYGQGAGTLNMDRGERLGIKPESVQPHRP
cCRP2 IHDAEVYCKSCYGKKYGPKGYGYGQGAGTLNMDRGERLGIKPESTPSPHP
hCRP2    IHDEE-  YCKSCYGKKYGPKGYGYGQGAGTLNMDRGERLGIKPESVQPHRP
NC                              /                                                      ////
                                                   150
IL-10E1 TTNPNTSKFAQKYGGAEKCSRCGDSVICCRKDNWSWKALAQKLFPMCKFW
r smLIM TTNPNTSKFAQKYGGAEKCSRCGDSVYAAEKIIGAGKPWHKNCFRCAKCG
hsmLIM   TTNPNTSKFAQKYGGAEKCSRCGDSVYAAEKIIGAGKPWHKNCFRCAKCG
hCRP2    TTNPNTSKFAQKYGGAEKCSRCGDSVYAAEKIIGAGKPWHKNCFRCAKCG
cCRP2            TTNPNTSKFAQKFGGAEKCSRCGDSVYAAEKVIGAGKPWHKNCFRCAKCG
NC          //////////////////////////////////////////////////////////     
IL-10E1 KNLESTTLTEKEGEIY-KGCYAKNFGPKGFGYGQGAGALVHAQ    -192
rsmLIM   KSLESTTLTEKEGEIYCKGCYAKNFGPKGFGYGQGAGALVHAQ  -193            
hsmLIM  KSLESTTLTEKEGEIYCKGCYAKNFGPKGFGYGQGAGALVHAQ  -193            
cCRP2 KSLESTTLTEKEGEIYCKGCYAKNFGPKGFGYGQGAGALVHAQ  -193
hCRP2   KSLESTTLTEKEGEIYCKGCYAKNFGPKGFGYGQGAGALVHAQ  -193
NC                     /                                    / 
Figure 2 Amino-acid sequence of IL-10E1 compared with amino-acid sequences of several other genes with 90–95% homology. Deduced amino-acid
sequences for IL-10E1; smooth muscle LIM (rsmLIM); human smooth muscle LIM (hsmLIM); chick CRP-2 (cCRP2); and human CRP-2 (hCRP2); NC-non-
concensus amino acids.
103
77
50
28.8
20.7
Lanes 1 2 3 4 5 6 7 8 9 101112
36 kDa
22 kDa
mwt
Figure 3 Western blots with IL-10E1 antibodies of whole-cell extracts
from (lanes 1–2) PC-3 ML cells and CPTX-1532 cells, respectively; (lane
3–12) four BPH lines, two HGPIN lines and four normal NPTX-1532 cell
lines, respectively, are shown. Cells were lysed, and the protein (1mgml
 1)
was electrophoresed on SDS–PAGE and Western blotted with a mixture
of IL-10E1 (0.1mgml
 1) and GADPH (0.5mgml
 1) antibodies. Top band
(36kDa) GADPH; bottom band (22kDa) IL-10E1.
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sextracts from these cells (Figure 5, lanes 1, 3). After 30, 60, and
120min stimulation, the majority of the rIL-10E1 was now present
in the nuclear extracts (Figure 5, lanes 5, 7, 9, respectively). The IL-
10E1 protein was no longer detectable in the cytoplasmic extracts
by B30–60min exposure to IL-10 (Figure 5, lanes 6 and 8) or by
90min (not shown). Similar studies of NPTX-1532 cells transfected
with the truncated rnt-nls construct showed that the B8.4kDa
peptide was expressed in the cytoplasmic fractions in unstimulated
cells (Figure 6, lane 1) and not in the nuclear fractions (Figure 6,
lane 2). Following IL-10 treatment for 10min, rnt-nls was detected
kDa
29
18.4
8.4
Lanes 1 2 3 4 5
kDa
97.4
68
43
29
18.4
Lanes 1 2 3 4
A
B
97.4
68
43
29
18.4
8.4
Lanes 1 2 3
kDa
C
Figure 4 (A) Western blots (of the same gel) with IL-10E1 antibodies (8–15% SDS–PAGE) of recombinant peptide fragments of the IL-10E1 gene,
including: (lanes 1–4) rnt-nls, rnt-nls mC61, rnt-nls mY57/mY62, and rnt-nls mY57/Y62, respectively and (lane 5) recombinant IL-10E1. (B) Western blots
with IL-10E1 antibodies (8% SDS–PAGE) of recombinant IL-10E1 peptides, including: (lanes 1–2) rnt-nls; (lane 3) rct and (lane 4) rnt fragments. (lane 2) the
IL-10E1 antibodies were preabsorbed with excess rIL-10E1 antigen. (C) Western blots of the same gel with IL-10E1 antibodies (8% SDS–PAGE) of crude
cytoplasmic protein extracts from NPTX-1532 cells transfected overnight with recombinant (lane 1) rnt-nls; (lane 2) rnt-nls mC61; (lane 3) nt-nls mY57/
mY62 constructs.
NN N N N CCC C kDa
97.4
68
43
29
22
123 4 5 6 7 8 9 Lanes
Figure 5 Western blots (8% SDS–PAGE) with IL-10E1 antibodies
comparing (matching) cytoplasmic (C) (lanes 2, 4, 6, 8) and nuclear (N)
(lanes 1, 3, 5, 7, 9) protein extracts from NPTX 1532 cells transfected with
the recombinant rIL-10E1 construct. Prior to harvesting, cells were exposed
to IL-10 for: (lanes 1–2) 0; (lane 3–4) 10; (lane 5–6) 30; (lane 7–8) 60
and (lane 9) 120min.
C NC NN CC
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kDa
Figure 6 Western blots (8% SDS–PAGE) with IL-10E1 antibodies
comparing (lanes 1, 3, 5, 6) cytoplasmic (C) and (2, 4, 7) nuclear protein
extracts from NPTX 1532 cells transfected with the recombinant rnt-nls
construct. Prior to harvesting, cells were exposed to IL-10 for: (lanes 1–2)
0; (lanes 3–4) 10; and (lanes 5–7) 30min.
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sin both cytoplasmic and nuclear protein extracts (Figure 6,
compare lanes 3, 4). In comparison, by 30min stimulation rnt-
nls was no longer detected in cytoplasmic extracts (Figure 6, lanes
5–6), but was detected in the nuclear extracts (Figure 6, lane 7).
Identical studies were also carried out with PC-3 ML human
prostate tumour cells, which normally expressed endogenous IL-
10E1 protein. Following transfection with the rnt-nls construct,
both nIL-10E1 and rnt-nls were expressed in cytoplasmic extracts
(data not shown). Following IL-10 stimulation, the presence of
both native nIL-10E1 and the rnt-nls peptide was assayed in
nuclear protein extracts. Neither protein was detected in the
nuclear extracts after 10 min stimulation (Figure 7A, lane 1).
However, both the intact nIL-10E1 protein and the nt-nls peptide
were detected in the nuclear protein fractions after B30–60min
(Figure 7A, lanes 2–3). Control experiments in Figure 7B (lanes 1–
3) showed that in the presence of IL-10R antibodies, IL-10 failed to
stimulate nIL-10E1 and rnt-nls translocation to the nucleus. Both
the 22kDa nIL-10E1 protein and 8.4kDa rnt-nls peptide remained
in the cytoplasmic fractions of cells exposed to IL-10 in the
presence of IL-10R antibodies for 10, 30, and 60min (Figure 7C,
lanes 1–3). The data indicate that the IL-10/IL-10R axis regulates
IL-10E1 signalling in nonmalignant and malignant prostate lines
and indicates that the nt-nls peptide may, in part, be functionally
equivalent to the intact nIL-10E1 protein.
JAK/TYK kinase studies
We postulated that the IL-10 receptor might regulate the IL-10E1
signalling cascade. To test this possibility, we initially employed
NPTX-1532 cells transfected with the rIL-10E1 construct. Cells
were treated with IL-10 and harvested to prepare crude protein
extracts for immunoprecipitation assays with excess phospho-
tyrosine-specific antibodies (PY20) (Figure 8A). The immunopre-
cipitates were then electrophoresed on SDS–PAGE gels and blotted
with JAK1- and TYK2-specific antibodies. Both antibodies blotted a
B130kDa band on the gels that corresponded to the JAK1 and
TYK2 proteins (arrowhead, Figure 8A, lanes 2 and 6, respectively).
In comparison, JAK3 antibodies failed to blot any detectable
protein (Figure 8A, lane 8), indicating that an IL-10-specific
receptor was involved. Western blot studies further showed that in
cells exposed to IL-10 in the presence of IL-10R antibodies, the
PY20 antibodies failed to immunoprecipitate JAK1, TYK2, or JAK3
(Figure 8A, lanes 1, 5, 7, respectively) from crude cell extracts,
presumably as a result of the receptor antibodies blocking IL-10’s
induction of IL-10 receptor phosphorylation. Figure 8A, lanes 3 and
4 show that secondary antibodies alone failed to blot the 130kDa
JAK and TYK bands. Note that the lower band (double arrowhead)
in lanes 2 and 6 appeared to be a nonspecific band inexplicably
blotted by both JAK1 and TYK2 antibodies. Western blots with IL-
10E1 antibodies (Figure 8B, lanes 1–8) confirmed that 22kDa rIL-
10E1 protein was uniformly expressed in the preparations blotted
in Figure 8A, and indicated that differences in protein content were
not a limiting factor in Figure 8A.
The immunoprecipitation studies were extended to examine
whether rIL-10E1 protein in transfected NPTX-1532 cells was also
phosphorylated in response to IL-10 ligand. Following IL-10
treatment for 60min, immunoprecipitates were isolated with PY20
antibodies from nuclear protein extracts. Western blots with IL-10
E1 antibodies showed that the immunoprecipitates from IL-10-
treated cells contained IL-10E1 protein (Figure 9A, lanes 1, 3). In
addition, immunoprecipitates prepared with IL-10E1 antibodies
were blotted with PY20 antibodies which labelled a 22kDa protein
(Figure 9A, lanes 4, 6), plus 1–2 associated proteins of unknown
composition. In control studies, IL-10 in the presence of IL-10R
antibodies failed to induce rIL-10E1 translocation to the nucleus
(Figure 9A, lanes 2, 5). That is, both PY20 and IL-10E1 antibodies
failed to immunoprecipitate the 22kDa protein from nuclear
extracts of these cells, and Western blots with IL-10E1 (Figure 9A,
lane 2) and PY20 (Figure 9A, lane 5) antibodies failed to detect the
22kDa protein in the respective immunoprecipitates. Control
experiments where the cells were incubated with IL-10 plus
secondary IgG antibody showed that the secondary antibodies did
not block IL-10 activation of the IL-10R. In these latter assays, the
IL-10E1 protein was immunoprecipitated with both PY20
(Figure 9A, lane 3) and IL-10E1 (Figure 9A, lane 6) antibodies
and blotted with IL-10E1 and PY20 antibodies, respectively.
Western blots of whole-cell extracts of the rIL-10E1-transfected
cells confirmed that rIL-10E1 protein was uniformly expressed by
the NPTX-1532 cells in these experiments (Figure 9B, lanes 1–6).
Site-directed mutagenesis studies
In attempts to identify whether specific tyrosine groups were
phosphorylated in response to IL-10 ligand, PC-3 ML cells were
kDa kDa
22
22
8.4
8.4
Lanes
1 2 3
Lanes
1 2 3
Lanes
1 2 3
A B C
Figure 7 (A–C) Western blots (6% SDS–PAGE) with IL-10E1 antibodies comparing nuclear protein extracts from PC-3 ML cells transfected with
a recombinant rnt-nls construct and exposed to: (A) IL-10 and (B) IL-10 plus IL-10R antibodies for (lane 1) 10; (lane 2) 30; and (lane 3) 60min. (C) Lanes
1–3 show blots of the matching cytoplasmic fractions from the cells in Figure (B), lanes 1–3, respectively. (lower band-rnt-nls); (upper band-nIL-10E1).
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stransfected with either rnt-nls (Figure 10A, lanes 1–2) or mutant
rnt-nls mY57/mY62 constructs (Figure 10A, lanes 3–4). In rnt-nls-
transfected cells, gel autoradiography of immunoprecipitates
isolated with the PY 20 antibodies showed that the nuclear
protein extracts from untreated cells did not contain either nIL-
10E1 or rnt-nls (Figure 10A, lane 1). Following IL-10 treatment, the
nuclear extracts contained both nIL-10E1 (arrowhead) and rnt-nls
peptide (double arrowhead) (Figure 10A, lane 2). In PC-3 ML cells
transfected with the rnt-nls mY57/mY62 expression vector, PY20
antibodies failed to immunoprecipitate the nt-nls mY57/mY62
peptide from nuclear extracts of untreated (Figure 10A, lane 3) and
IL-10-treated cells (Figure 10A, lane 4). In comparison, the nIL-
10E1 protein was barely detectable in nuclear extracts of untreated
cells (Figure 10A, lane 3), but was significantly elevated in nuclear
extracts of IL-10-treated cells (Figure 10A, lane 4, arrowhead).
Western blots with IL-10E1 antibodies of cytoplasmic extracts
verified that nIL-10E1 and rnt-nls mY57/mY62 peptides were both
expressed in the cytoplasmic protein extracts of untreated PC-3
ML cells (data not shown). Western blots with IL-10E1 antibodies
further showed that the immunoprecipitates prepared with PY20
antibodies from cytoplasmic and nuclear protein fractions of the
IL-10-treated cells did not contain detectable levels of rnt-nls
mY57/mY62 peptide, indicating that the PY20 antibodies failed to
recognise nonphosphorylated protein. The nIL-10E1 protein was
detected in Western blots of the PY20 antibody immunoprecipi-
tates prepared from the nuclear extracts of IL-10-treated cells. The
truncated rnt-nls mY57/mY62 peptide was not detected in these
assays (data not shown), presumably because IL-10 failed to
induce its translocation to the nucleus.
Identical experiments were carried out with normal NPTX-1532
cells transfected with either rnt-nls or rnt-nls mY57/mY62
constructs (Figure 10B). Gel autoradiography of immunoprecipi-
tates prepared with PY20 antibodies showed that nuclear extracts
from cells exposed to IL-10 for 120min (i.e. NPTX-1532 cells
transfected with the rnt-nls mY57/mY62 construct) did not contain
the rnt-nls mY57/mY62 peptide (Figure 10B, lane 1). In contrast,
the rnt-nls peptide was detected in nuclear extracts (i.e. from
NPTX-1532 cells transfected with the rnt-nls construct) following
exposure of the cells to IL-10 for 120min (Figure 10B, lane 2). That
is, the phosphorylated rnt-nls peptide was immunoprecipitated
with PY20 antibodies from the nuclear extracts of these cells
(Figure 10B, lane 3). Control experiments showed that the rnt-nls
peptide was not immunoprecipitated from nuclear extracts of
NPTX-1532 cells (transfected with the rnt-nls construct) exposed
to IL-10 in the presence of IL-10R antibodies (Figure 10B, lane 3).
kDa
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1 234 5 6 7 8 Lanes
kDa
22
1 234 5 6 7 8
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Lanes
Figure 8 (A) Western blots (8% SDS–PAGE) with: Fig. 8A: (lanes 1, 2)
JAK 1, (lanes 3, 4) secondary antibody alone, (lanes 5, 6) TYK2 and (lanes 7,
8) JAK 3 antibodies. NPTX 1532 cells were transfected with recombinant
rnt-nls and treated with IL-10 in the (lanes 1, 3, 5, 7) presence and (lanes 2,
4, 6, 8) absence of IL-10 receptor antibodies (1:100 dilution).
Phosphorylated proteins were immunoprecipitated with PY20 antibodies
from whole-cell extracts for Western blots. (arrowhead) Top band-specific
antibody binding (double arrowhead) Lower band-nonspecific antibody
binding. (B) Lanes 1–8. Western blots with IL-10E1 antibodies of whole-
cell extracts from IL-10E1-transfected NPTX-1532 cells. IL-10E1 was
uniformly expressed in the different studies described in (A), Lanes 1–8.
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Figure 9 (A) Western blots with (lanes 1–3) IL-10E1 and (lanes 4–6)
PY20 antibodies of immunoprecipitates obtained from nuclear protein
extracts of rIL-10E1-transfected NPTX-1532. Cells were pretreated for
60min with: (lanes 1 and 4) IL-10; (lanes 2 and 5) IL-10+IL-10R antibodies;
and (lanes 3 and 6) IL-10 plus secondary IgG antibodies. (B) Lanes 1–6.
Western blots with IL-10E1 antibodies of whole-cell extracts from
untreated NPTX-1532 cells in Figure 8A, lanes 1–6, respectively.
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sWestern blots with IL-10E1 antibodies of cytoplasmic extracts
from the untreated NPTX-1532 cells confirmed that both rnt-nls
(Figure 10C, lane 1) and rnt-mY57/mY62 peptides (Figure 10C,
lane 2) were expressed in the NPTX-1532 cells lines transfected
with their respective constructs. The rnt-nls peptide was not
detected in NPTX-1532 cells transfected with vector alone (Figure
10C, lane 3). These data indicate that an intact rnt-nls peptide (i.e.
with Y57 and Y62 tyrosines) was required for the nuclear
localisation of the rnt-nls peptide and the IL-10E1. Note that the
2–3 bands at the top of the gel in Figure 10A and B were
phosphorylated proteins of unknown identity, which were
uniformly precipitated with the PY20 antibodies from extracts of
both untreated and IL-10-treated cells.
Regulation of TIMP-1 expression
Preliminary studies were carried out to assess if IL-10 activation of
rIL-10E1 or the rnt-nls peptide induced TIMP-1 expression in
transfected NPTX-1532 cells. ELISA measurements showed that
NPTX-1532 cells (Figure 11, -) and mock-transfected NTPX-1532
cells (Figure 11, X) (i.e. cells transfected with vector alone)
normally expressed (secreted) barely detectable levels of TIMP-1
protein in the absence or presence of increased levels of IL-10.
However, following transient transfection overnight with either the
IL-10E1 or the nt-nls construct, IL-10 (0–60ngml
 1 for 24h)
induced TIMP-1 expression in a dosage-dependent manner in
these NPTX-1532 subclones (Figure 11, m’). IL-10 receptor
antibodies blocked IL-10 induction of TIMP-1 expression by cells
transfected with the rnt-nls construct (Figure 11, K) and the rIL-
10E1 expression vector (data not shown). In comparison, NPTX-
1532 subclones transfected with the rnt-mY57/mY62 construct
failed to secrete TIMP-1 in response to IL-10 at increased dosages
for 24h (Figure 11, E). These experiments indicate that IL-10
activation of the rIL-10E1 protein or the truncated rnt-nls peptide
stimulated TIMP-1 production. Since IL-10 failed to induce TIMP-
1 expression in NPTX-1532 cells transfected with the nt-mY57/mT
62 peptide, we suggest that the intact nt-nls peptide was required
for the signalling cascade and that IL-10-induced phosphorylation
of specific tyrosine groups (e.g. Y57 and Y62) may regulate
activation of the IL-10E1 protein and nt-nls peptide to control
TIMP-1 synthesis.
DISCUSSION
In two earlier papers, we found that the IL-10 stimulated activation
of the HTE-1 enhancer element of the TIMP-1 gene to activate
TIMP-1 expression in malignant human prostate cell lines (Wang
et al, 1998, 2002). In this paper, the data significantly extended
these studies and showed that IL-10 ligand binding to the IL-10
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Figure 10 (A) Immunoprecipitates with PY20 antibodies of nuclear extracts from PC-3 ML cells. Cells were transiently transfected o.n. with recombinant
(lanes 1–2) rnt-nls (B8.4kDa); and (lane 3–4) rnt-nls mY57/MY62 constructs and then (lanes 1, 3) untreated; or (lanes 2–4) treated with IL-10.
Arrowhead: nIL-10E1–22kDa; double arrowhead: 8.4kDa peptide. The three bands at the top of the gel are phosphorylated proteins present in all the
PY20 immunoprecipitates. (B) Immunoprecipitates with PY20 antibodies of nuclear extracts from NPTX-1532 cells. Cells were transfected with (lane 1) rnt-
mY57/mY62 and (lanes 2–3) rnt-nls constructs. The cells were exposed to IL-10 for (lane 1) 0min and (lane 2) 60min, and (lane 3) IL-10 + IL-10R abs for
60min. (C) Western blots with IL-10E1 antibodies of cytoplasmic protein extracts from the NPTX-1532 cells confirmed that (lane 1) rnt-nls, (lane 2) rnt-
mY57/mY62 peptides were expressed in the cytoplasm of untreated cells. (Lane 3) cells transfected with vector alone.
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Figure 11 ELISA measurements of TIMP-1 secreted over 24h by
NPTX-1532 cells in the presence of IL-10 at concentrations ranging from
10 to 60ngml
 1 for 24h. NPTX-1532 cells were ( ) not transfected; (x)
mock-transfected with vector alone; or transfected with (m) rIL-10E1; (’)
rnt-nls; and (~) rnt-mY57/mY62 expression vectors. NPTX-1532 cells
were transfected with (K) rnt-nls and exposed to IL-10 in the presence of
IL-10R antibodies. Values represent the mean+1 s.d. from at least three
experiments and triplicate measurements per experiment.
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sreceptor activated a signal cascade, which rapidly activated TIMP-
1 expression in normal and malignant prostate cell lines. That is,
IL-10 binding to the IL-10R induced tyrosine phosphorylation of
the JAK 1/TYK2 kinases, tyrosine phosphorylation of Y57 and Y62
tyrosines in the ‘n-terminal’ domain of the IL-10E1 protein, and
the rapid transport to the nucleus of the IL-10E1 protein.
Immunoprecipitation assays showed that phosphorylation of
Y57/Y62 tyrosines triggered redistribution of the intact IL-10E1
protein and the nt-nls fragment in both normal and malignant
human prostate cell lines. The nt-nls mY57/mY62 fragments
containing mutated tyrosines were not phosphorylated following
IL-10 treatment of transfected cells and the nt-nls peptide failed to
migrate to the nucleus in these cells. In addition, nuclear
translocation of the nt-nls fragment (and presumably the intact
IL-10E1 protein as well) required the nls, but not the remaining c-
terminal domain of the IL-10E1 protein. This indicates that the
mechanism of activation of the nls region may involve changes in
protein–protein interaction, or perhaps conformational
changes in the IL-10E1 protein mediated by tyrosine phosphoryla-
tion of Y57 and Y62 groups. In sum, the data from the site-
directed mutagenesis and deletion analysis studies uniformly
confirmed that the n-terminal domain, and specifically the region
spanning about 17 a.a.’s (e.g. YCKSCYGKKYGPKGYGY), were
primarily responsible for nuclear translocation of the IL-10E1
protein. We believe that this domain may possibly control binding
to the HTE-1 element and activation of TIMP-1 expression. The
data presented in Figure 10 clearly showed that IL-10 activation of
IL-10E1 signalling serves to upregulate TIMP-1 in NPTX-1532
cells, but the precise mechanism controlling the molecular process
has yet to be defined. Preliminary EMSA studies in our laboratory
have shown that the nt-nls fragment binds the HTE-1 site, but the
truncated n-terminal fragments lacking the YCKSCYG domain
failed to bind the HTE-1 site. In addition, other EMSA studies have
indicated that IL-10-induced tyrosine phosphorylation of the
intact nt-nls peptide or the IL-10E1 protein promoted a 4–5 fold
increase in binding activity compared to nonphosphorylated
protein and recombinant protein from phagemid expression
vectors (data not shown). The significance of these observations
is currently under study in hopes of understanding how binding
interactions of the YCKSCYG domain with specific nucleotide
sequences of the HTE-1 element serve to regulate TIMP-1
expression.
Interestingly, the sequence data reported in this paper indicate
that IL-10E1 is a ‘LIM-domain’ protein with a 495% homology to
CRP2 and hsmlim genes (Weiskirchen et al, 1997). Sequence
comparisons from GenBank indicated that there was 100%
homology in the 50 region spanning the first LIM domain of the
CRP2 and hsmlim genes. However, the region spanning the second
LIM-domain (B +451 to +490bp)(i.e. exons 2–3) exhibited
B90% homology with CRP2 and hsmlim genes (Weiskirchen et al,
1997). The deduced amino-acid sequence revealed that unlike
CRP2 and hsmlim proteins (Dawid et al, 1995, 1998; Weiskirchen
et al, 1997), which expressed two LIM domains, the IL-10E1
protein consisted of a single LIM domain at the n-terminal region
of the protein. Presumably, this difference between IL-10E1 and
CRP2 or hsmlim might explain why IL-10E1 is overexpressed in
prostate cancer cells and functions as an IL-10-responsive signal
molecule.
In brief, the LIM motif is a ‘helix-loop-helix’ domain that was
originally identified in three developmentally regulated transcrip-
tion factors, Caenorhabditis elegans Lin-11, rat Isl-1, and C.
elegans Mec-3 (Freyd et al, 1990; Karlsson et al, 1990), but has
since been identified in a variety of proteins. The LIM domain
consists of a 52 amino-acid sequence CX2CX16–23HX2
CX2CX2CX16–21CX2–3(C/H/D) motif, which typically has been
associated with DNA-binding homeodomains and kinase domains
(Freyd et al, 1990; Karlsson et al, 1990; Dawid et al, 1995, 1998).
The LIM domain has been recognised as a distinct protein motif
within LIM homeodomain proteins by both genetic and biochem-
ical methods (Freyd et al, 1990; Karlsson et al, 1990; Way and
Chalfie, 1994). The LIM domain has been found to mediate
‘protein–protein’ interactions of cytoplasmic and nuclear proteins.
NMR analysis of the solution structure of the c-terminal LIM
domain of two of these proteins, CRP1 (Perez-Alvarado et al, 1994)
and CRP2 (Konrat et al, 1997; Weiskirchen et al, 1997; Wadman
et al, 1994), has shown that two zinc-fingers constitute a LIM
domain, which represent two separated structural entities held
together in a distinct configuration by hydrophobic interactions
(Dawid et al, 1998). Moreover, the c-terminal LIM domain in CRP1
and CRP2 has been found to closely resemble the zinc-finger in the
DNA-binding domain of GATA1, suggesting that the LIM domain
might specifically bind DNA (Weiskirchen et al, 1995).
There is a potpourri of evidence indicating that LIM home-
odomain proteins or LHX proteins function as transcription
factors and genetic evidence has supported this idea (Dawid et al,
1998). Several studies have shown that LIM-homeo-
domain proteins can activate the expression of specific genes
(i.e. insulin) or direct cellular differentiation in cooperation
with other nuclear factors (Perez-Alvarado et al, 1994). Other
examples include, E47/Pan-1 and Lmx1.1 transcription factors,
which have been shown to interact with LMO2, a LIM only protein,
and with TAL1, LYL1, and LYL2 to regulate gene activation
(Sadler et al, 1992; Warren et al, 1994; Larson et al, 1996;
Johnson et al, 1997; Dawid et al, 1998). Similarly, the rat
cysteine-rich intestinal protein (CRIP), the human cysteine-rich
protein (CRP), and rhombotin-1 and -2 have been implicated as
protein crosslinkers in transcription regulation (Dawid et al, 1998).
The IL-10E1 protein belongs to the LIM only homeodomain
family of proteins, which bind specific cognate DNA elements to
regulate gene expression (Dawid et al, 1998). Part of the LIM
domain, the YCKSCYG region, appears to directly mediate
binding, but the entire LIM domain and the ‘helix–loop–helix’
conformation of the 52 a.a. LIM domain is probably important for
specific binding to the TIMP-1 promoter and the stimulation of
TIMP-1 expression.
In conclusion, we have shown for the first time that IL-10
signalling in prostate cell lines involves a signal pathway distinct
from the STAT 1/STAT 3 pathway identified in white blood cell
lines. The signal cascade activates a novel LIM only protein,
termed IL-10E1, which is phosphorylated at two specific tyrosine
groups, Y57/Y62, to activate signalling and binding to the TIMP-1
promoter. As a consequence, TIMP-1 expression is upregulated.
Since TIMP-1 overexpression has been associated with the
blockade of metastasis in human prostate tumour xenograph
model studies (Stearns et al, 1999), we suggest that IL-10 may
indirectly prevent tumour metastasis by this mechanism. IL-10
does not appear to alter IL-10E1 levels since ELISA measurements
indicate that PC-3 ML cells express pictogram quantities (10–
30pgml
 1) independent of IL-10. Also, in NPTX-1532 cells which
do not normally express detectable IL-10E1, IL-10 failed to induce
expression.
The preliminary studies further indicate that the IL-10/IL-10R
axis and activation of IL-10E1 stimulates the upregulation of
TIMP-1 production in NPTX-1532 cells. Thus, the IL-10/IL-10R
axis is of import in controlling tumour metastasis and the
development of therapeutic approaches which target this pathway
is ongoing in our lab. Recently, green fluorescent protein has been
employed to tag regulatory proteins and analyse the mechanisms
controlling nuclear translocation in real-time. For example,
Hagting et al (1999) showed in real-time studies that the
translocation of fluorescently tagged wild-type (wt) cyclin B1 was
controlled by phosporylation. In these studies, we will utilise cells
transfected with wt and mutant IL-10E1 proteins tagged with green
fluorescent protein to identify (in real time) therapeutic agents that
specifically block signalling in response to specific ligands (IL-10,
IL-4, INF).
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